Hybrid dendrimer hydrogel/poly(lactic-Co-glycolic acid) nanoparticle platform: An advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 166-172

  Yang, Hu ^a,b   Leffler, Christopher T ^c  

^a Virginia Commonwealth University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DENDRIMER; DRUG VEHICLE; HYBRID DENDRIMER HYDROGEL/POLY(LACTIC CO GLYCOLIC ACID) NANOPARTICLE PLATFORM; MACROGOL; NANOPARTICLE; POLYAMIDOAMINE; POLYGLACTIN; TIMOLOL; UNCLASSIFIED DRUG;

CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUTION; GLAUCOMA; HUMAN; HYDROGEL; PATIENT COMPLIANCE; REVIEW;

ADMINISTRATION, OPHTHALMIC; ANIMALS; DENDRIMERS; DRUG DELIVERY SYSTEMS; GLAUCOMA; HUMANS; HYDROGEL; LACTIC ACID; MEDICATION ADHERENCE; POLYGLYCOLIC ACID;

EID: 84875017022     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0197     Document Type: Review

References (20)

1. Varma, R., Lee, P.P., Goldberg, I., & Kotak, S. An assessment of the health and economic burdens of glaucoma. Am. J. Ophthalmol. 152:515-522, 2011.
2. Leffler, C.T., & Amini, L. Interpretation of uniocular and binocular trials of glaucoma medications: an observational case series. BMC Ophthalmol. 7:17, 2007.
3. Lele, B.S., & Hoffman, A.S. Insoluble ionic complexes of polyacrylic acid with a cationic drug for use as a mucoadhesive, ophthalmic drug delivery system. J. Biomater. Sci. Polym. Ed. 11:1319-1331, 2000.
4. Rozier, A., Maznel, C., Grove, J., & Plazonnet, B. Gelrite: a novel, ion activated, in situ gelling polymer for ophthalmic vehicles-effect on bioavailability of timolol. Int. J. Pharm. 57:163-168, 1989.
5. Zimmer, A., Mutschler, E., Lambrecht, G., Mayer, D., and Kreuter, J. Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system. Pharm. Res. 11:1435-1442, 1994.
6. Desai, P.N., Yuan, Q., & Yang, H. Synthesis and characterization of photocurable polyamidoamine dendrimer hydrogels as a versatile platform for tissue engineering and drug delivery. Biomacromolecules. 11:666-673, 2010.
7. Holden, C.A., Tyagi, P., Thakur, A., Kadam, R., Jadhav, G., Kompella, U.B., & Yang, H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine. 8:776-783, 2012.
8. Yang, H., Tyagi, P., Kadam, R.S., Holden, C.A., & Kompella, U.B. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 6:7595-7606, 2012.
9. Tomalia, D.A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., & Smith, P. A new class of polymers: starburst-dendritic macromolecules. Polym. J. (Tokyo). 17:117-132, 1985.
10. Tomalia, D.A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., & Smith, P. Dendritic macromolecules: synthesis of starburst dendrimers. Macromolecules. 19:2466-2468, 1986.
11. Yang, H., & Lopina, S.T. Penicillin V-conjugated PEGPAMAM star polymers. J. Biomater. Sci. Polym. Ed. 14:1043-1056, 2003.
12. Yang, H., Morris, J.J., & Lopina, S.T. Polyethylene glycolpolyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J. Colloid Interface Sci. 2004; 273:148-154.
13. Yang, H., & Lopina, S.T. In vitro enzymatic stability of dendritic peptides. J. Biomed. Mater. Res. Part A 76A:398-407, 2006.
14. Yang, H., & Kao, J.W. Synthesis and characterization of nanoscale dendritic RGD clusters for potential applications in tissue engineering and drug delivery. Int. J. Nanomedicine. 2:89-99, 2007.
15. Sarkar, K., & Yang, H. Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv. 15:343-346, 2008.
16. Bravo-Osuna, I., Noiray, M., Briand, E., Woodward, A.M., Argueso, P., Molina Martinez, I.T., Herrero-Vanrell, R., and Ponchel, G. Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance. Pharm. Res. 29:2329-2340, 2012.
17. Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, J.P., Parrish, R.K., 2nd, Wilson, M.R., and Gordon, M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-Angle glaucoma. Arch Ophthalmol. 120:701-713; discussion 829-730, 2002.
18. Kobelt-Nguyen, G., Gerdtham, U.G., & Alm, A. Costs of treating primary open-Angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J. Glaucoma. 7:95-104, 1998.
19. Savolainen, J., Rautio, J., Razzetti, R., & Jarvinen, T. A novel D2-dopaminergic and alpha2-Adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits. J. Pharm. Pharmacol. 55:789-794, 2003.
20. Gupta, S.K., Agarwal, R., Galpalli, N.D., Srivastava, S., Agrawal, S.S., & Saxena, R. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Methods Find. Exp. Clin. Pharmacol. 29:665-671, 2007.